Should deferiprone be withheld during a mild urinary tract infection, and when can it be safely resumed?

Deferiprone Management During Mild Urinary Tract Infection

Deferiprone should be temporarily interrupted during a mild urinary tract infection and can be safely resumed once the infection has resolved and the absolute neutrophil count (ANC) is ≥1.5 × 10⁹/L.

Rationale for Withholding

The FDA drug label explicitly states that deferiprone must be interrupted if infection develops, with frequent ANC monitoring required 1. This recommendation is driven by two critical safety concerns:

• Neutropenia risk: Deferiprone causes neutropenia (ANC 0.5-1.5 × 10⁹/L) in approximately 5% of patients, particularly in association with viral infections 2. While the evidence specifically mentions viral infections, the principle applies to any infectious process that could compound neutropenia risk.

• Agranulocytosis risk: Fatal agranulocytosis (ANC <0.5 × 10⁹/L) occurs in approximately 1-1.7% of patients 2, 1. The mechanism is unknown, but the combination of infection plus deferiprone creates unacceptable risk for life-threatening neutropenia.

Management Algorithm

During the UTI:

1. Immediately discontinue deferiprone when UTI symptoms develop (fever, dysuria, urgency)
2. Obtain baseline CBC with ANC before treating the UTI
3. Treat the UTI with appropriate antibiotics per standard guidelines
4. Monitor ANC frequently (at minimum every 2-3 days) during the infection

For resumption after UTI resolution:

1. Confirm clinical resolution of UTI symptoms (typically 5-7 days of appropriate antibiotics for uncomplicated UTI) 3
2. Verify ANC ≥1.5 × 10⁹/L before restarting deferiprone 1
3. Resume deferiprone at previous dose once both conditions are met
4. Continue weekly ANC monitoring for at least 2-4 weeks after resumption to detect delayed neutropenia

Critical Pitfalls to Avoid

Do not continue deferiprone during active infection. The FDA label is unequivocal: "Interrupt deferiprone if infection develops" 1. This supersedes concerns about brief interruption of iron chelation, as the mortality risk from agranulocytosis outweighs short-term iron accumulation.

Do not restart without checking ANC. Even if the patient feels better, neutropenia may be asymptomatic. The ANC must be documented as ≥1.5 × 10⁹/L before resumption 1.

Do not assume the UTI is "too mild" to warrant interruption. The guideline evidence shows that neutropenia occurs "particularly in association with viral infections" 2, suggesting any infectious stimulus can trigger this complication. A mild UTI still represents an infectious challenge that increases neutropenia risk.

Duration of Interruption

Most uncomplicated UTIs resolve within 5-7 days of appropriate antibiotic therapy 3. Therefore, deferiprone interruption typically lasts 7-10 days (duration of UTI treatment plus time to verify ANC recovery). This brief interruption poses minimal risk to iron burden management, as the American Heart Association guidelines note that iron chelation effects occur over months to years 2.

For men with febrile UTI: If acute bacterial prostatitis is suspected, antibiotic duration extends to 10-14 days 3, meaning deferiprone interruption would last approximately 14-17 days.

Special Considerations

The renal excretion of deferiprone (75-90% urinary) 2 is not a contraindication during UTI, but rather reinforces the need for interruption since the urinary tract is the site of active infection. Research shows deferiprone pharmacokinetics are not significantly altered by renal impairment 4, so dose adjustment is not needed upon resumption unless renal function has deteriorated.